Strategic Vaccines

A public private partnership

Strategic Vaccines LLC is a public private partnership to test and deploy FLOVID-20, an inhaled treatment for COVID-19 designed to keep COVID positive patients out of the hospital.

 

About Strategic Vaccines

A solution after diagnosis

Our targeted immunotherapy is a medical breakthough that can offer doctors a solution after receiving a positive test for SARS-CoV-2. 

Watch the video to learn more about the gap in options between vaccination and treatment.

Under Development, FDA Approval Required

Currently Manufacturing in Solon, Ohio

Our goal is to prevent those infected with SARS-CoV-2 from progressing to the serious consequences of COVID-19. Our targeted T-cell immunotherapy is currently being manufactured at Oakwood Laboratories, and we’re planning to conduct clinical studies in Cleveland.

Proven effective

Tested at the Galveston National Laboratory, we were able to prevent pneumonia in primates by giving them FLOVID-20 by inhalation then infecting them with SARS-CoV-2.

Watch the video below to see how we used our targeted T-cell immunotherapy to deliver FLOVID-20 by inhalation to protect non-human primates from SARS-CoV-2 infection.

Targeted T-Cell Immunotherapy

Our targeted T-cell immunotherapy delivery platform offers a unique solution in identifying and destroying infected cells, and may be used after the patient has been infected.

Watch the video below to learn more about how the targeted T-cell immunotherapy delivery platform works.

The COVID-19 Diagnosis and Treatment Path

  • Pre-Diagnosis

    Vaccine development

    Priority funding is going into developing a vaccine that can be distributed to an uninfected subject.

  • Contracted SARS COVID-2

    Opportunity for FLOVID-20

    Currently, there are no options specifically for a patient that has been diagnosed, but is still healthy and doesn’t require hospitalization.

  • COVID-19 Hospitalization

    Hospitalization and Therapy

    Priority funding is going into developing therapies once the patient is in urgent care.

Pre-diagnosis

Vaccine development

Priority funding is going into developing a vaccine that can be distributed to an uninfected subject.

Contracted SARS COVID-2

Opportunity for FLOVID-20

Currently, there are no options specifically for a patient that has been diagnosed, but is still healthy and doesn’t require hospitalization.

COVID-19 Hospitalization

Hospitalization and Therapy

Priority funding is going into developing therapies once the patient is in urgent care.

Founding companies

Home

Partner companies

Contact us for more information